Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immatics Biotechnologies GmbH

www.immatics.com

Latest From Immatics Biotechnologies GmbH

Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera

AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.

Deals Commercial

Genmab Moves On From Darzalex/Tecentriq Failure With Bispecifics Deal

Genmab is planning for its post-Darzalex future by exploring bispecific immunotherapies in a collaboration with Immatics that should see it develop immunotherapies directed against three proprietary targets, with the option of two more.

Cancer Companies

Venture Funding Deals: From ADC To Y-mAbs, Capital Flows For New Platforms, Novel Approaches

October was an active fundraising month for both start-up biopharma companies and more established privately held firms, ranging from $3m for Appili's drug for anaerobic infections to $270m for Harmony's rare disease programs.

Financing Commercial

Finance Watch: J&J Notes JLabs Incubators' Success Stories To Date

Private Company Edition: Life science firms in J&J's JLabs incubators have raised $9.4bn to date from deals and financings, including five IPOs. Also, October brings a wide range of new equity and VC financings.

StartUps and SMEs Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Immatics Biotechnologies GmbH
  • Senior Management
  • Thomas Ulmer, CFO
    Carsten Reinhardt, MD, PhD, CMO
    Harpreet Singh, PhD, CSO
    Rainer Kramer, PhD, CBO
  • Contact Info
  • Immatics Biotechnologies GmbH
    Phone: (49) 70 71 5397 0
    Paul-Ehrlich Str. 15
    Tuebingen, 72076
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register